Piper Jaffray Downgrades Anthera Pharma (ANTH) to Underweight; PT $0.10
Tweet
Share
E-mail
Get Alerts ANTH Hot Sheet
Price: $0.00 --0%
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Piper Jaffray downgraded Anthera Pharma (NASDAQ: ANTH) from Overweight to Underweight with a price target of $0.10 (from $4.00) after Phase III RESULTS trials missed and Sollpura suspended.
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $0.33 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic CFO Krishna Rao is leading early IPO meetings with investors and has not discussed valuation - CNBC
- Sansera Engineering Ltd (SANSERA:IN) PT Raised to INR4,250 at ICICI Securities
- Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
